Navigation Links
Kun Run Biotechnology, Inc. Year-End Revenues Increase 56% to $11.6 million
Date:4/1/2009

HAIKOU, China, April 1 /PRNewswire-Asia-FirstCall/ -- Kun Run Biotechnology, Inc., (OTC Bulletin Board: KURU) a leading bio-pharmaceutical company in China that focuses on manufacture and sales of peptides and peptide-based drugs, today announced its financial results for the year ended December 31, 2008.

Revenues for the year ended December 31, 2008 were $11.6 million, an increase of $4.1 million, or 56% over revenues for the same period of 2007.

The gross margin for the year ended December 31, 2008 was 71%, increasing from 58% for the same period of 2007. Selling expenses were $687,949 or 6% of the total sales, for the year ended December 31, 2008, decreasing 51% from $1,416,469 for 2007. The drop was mainly due to the Company's increased marketing budget in 2007 in order to enlarge sales and market share. These expenditures fell back to a more normal level in 2008 as our brands reached a more mature position and extra promotions were not as necessary. Research and development expenses were $271,476 in 2008, equivalent to $276,138 in 2007.

Income from operations increased 262% to $4.8 million in 2008 from $1.7 million for the year ended December 31, 2007. The sharp increase in income from operations was in part due to strong marketing and sales efforts and efficient cost control systems.

Net income increased 378% to approximately $6.0 million for the year ended December 31, 2008. This was an improvement of approximately $4.8 million, from approximately $1.2 million for the same period of 2007. Comprehensive income was $6.8 million compared to $1.4 million in 2007. This increase was in line with the revenue growth and margin improvement and reflects income from disposing property that contributed an additional $2.4 million. Earnings per share for the year ended December 31, 2008 were $0.24 per share (both basic and diluted), compared with $0.05 per share (both basic and diluted
'/>"/>

SOURCE Kun Run Biotechnology, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc.
2. Champions Biotechnology, Inc. Appoints New Board Members and Forms Management Team
3. Champions Biotechnology, Inc. Completes $2,500,000 Private Financing at $1.75 per Share
4. Letter to Shareholders from the CEO and Chairman of the Board of Yongye Biotechnology, Inc.
5. Dynatronics to Release Fourth Quarter and Year-end Results Friday, September 14, 2007; Conference Call set for 1:00 p.m. ET
6. Neurobiological Technologies, Inc. Reports Fourth Quarter and Fiscal Year-End Financial Results for 2007 Announces 1-for-7 Reverse Stock Split
7. Bioniche Reports Fiscal 2007 Year-End Results
8. Alfacell to Host Fiscal Fourth Quarter and Year-End 2007 Financial Results Conference Call and Webcast
9. Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results
10. Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results
11. Vasogen to Conduct Year-end 2007 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Jan. 14, 2014 The largest international professional ... plants and therapeutic derivatives thereof has endorsed an ... researchers about the challenges of adulterated herb and ... The Society for Medicinal Plant ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility management software, ... Strategy. In this role, Michelle will work with current and ... the development of iLab products. Her main goal will be ... the scientific community by offering the most advanced, user-friendly, and ...
(Date:1/14/2014)... Mass. , Jan. 14, 2014  RXi Pharmaceuticals ... discovering, developing and commercializing innovative therapies addressing major ... that it received the Notice of Allowance from ... its unique self-delivering RNAi compounds (sd-rxRNA®), for the ...
(Date:1/14/2014)... 14, 2014   Kinaxis ®, provider of RapidResponse ®, ... and operations planning ( S&OP ) service, is proud to ... which will be held at the Hilton San Diego Bayfront, ... customer Elisabeth Kaszas , Director of Supply Chain at ...
Breaking Biology Technology:World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... Co-founder Recognized for Role in Engineering Microbes to Produce ... TR35 2007 Recipients to be Honored at Technology Review,s Emerging ... ... Amyris Biotechnologies is,pleased to announce that Neil Renninger, Ph.D., co-founder ...
... 13 PharmAthene, Inc.,(Amex: PIP ) a ... and chemical threats, announced today,that proceedings have been ... validity of the merger between Healthcare Acquisition Corp. ... Chancery will determine that the Merger was,validly approved ...
... BioVex Inc, a biotechnology,company developing clinical stage treatments ... today that it has appointed Dr. Thaddeus,Pullano, 53, ... http://www.newscom.com/cgi-bin/prnh/20070815/NYW022 ) Previously, Dr. Pullano ... Acambis from 2003 to 2007. In this role, ...
Cached Biology Technology:Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Review's Prestigious TR35 List of Top Young Innovators 2Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Review's Prestigious TR35 List of Top Young Innovators 3Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court 2BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance 2
(Date:7/9/2014)... JOLLA-The ability to switch out one gene for another ... crossed from science fiction to reality within this decade. ... both promise--the hope of fixing disease-causing genes in humans, ... Salk scientists have put one of those concerns to ... the overall occurrence of mutations in the cells. The ...
(Date:7/9/2014)... - Regulated deer hunts in Indiana state parks have ... of damage caused by overabundant populations of white-tailed deer, ... by Michael Jenkins, associate professor of forest ecology, found ... of organizing hunts in state parks has successfully spurred ... rendered scarce by browsing deer. , Jenkins said ...
(Date:7/9/2014)... Scientists from the Spanish National Cancer Research Centre (CNIO) ... stem cells, also regulates cell division in stratified epitheliathose ... or cover the oesophagus or the vaginain adult organisms. ... the journal Nature Communications , this factor could ... derived from stratified epithelia of the oesophagus and skin. ...
Breaking Biology News(10 mins):No extra mutations in modified stem cells, study finds 2No extra mutations in modified stem cells, study finds 3Hunting gives deer-damaged forests in state parks a shot at recovery 2CNIO scientists discover that pluripotency factor NANOG is also active in adult organisms 2
... to Josef Ackermann, the head of Deutsche Bank. At almost ... in Rome. The hand of the manager in charge of ... or security staff have had to conduct painstaking inspections of ... approach. At the end of 2011, though, the scanner T-Cognition ...
... release is available in German . ... from Siegen and Professor Jacek Błażewicz from Poznan have ... (DFG, German Research Foundation) and the Foundation for Polish ... scientific collaboration. "The two researchers perform outstanding research, are ...
... groundbreaking new gene sequencing technology, researchers have demonstrated that ... Acute Myeloid Leukemia, AML, one of the most common ... Pacific Biosciences, allows for the rapid and comprehensive detection ... findings, published online April 15 in Nature , ...
Cached Biology News:On the safe side: Contact-free analysis of chemical substances 2Copernicus Award 2012 for German-Polish collaboration in business information systems 2Copernicus Award 2012 for German-Polish collaboration in business information systems 3Scientists identify FLT3 gene as a valid therapeutic target in acute myeloid leukemia 2
Adhesive seal-tab, for HybriWell™ hybridization sealing system *set of 400*...
... cell culture systems provide an integrated ... staining and imaging. Each system uses ... optical-quality coverslips in cell culture plates. ... and ready to use. Individual chambered ...
RECOMBINANT EQUINE IL-4 Product Type: Recombinant Protein...
RECOMBINANT EQUINE TNF ALPHA Product Type: Recombinant Protein...
Biology Products: